Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Pfizer identified a clinical need for an intravenous formulation of its antifungal compound, voriconazole, which was also available as an oral tablet. Captisol addressed voriconazole's technical challenge of low solubility by achieving a high concentration for an intravenous dosage form.
